Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (2016 - 2025)

Agios Pharmaceuticals' Shares Outstanding history spans 14 years, with the latest figure at $58.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 2.26% year-over-year to $58.4 million; the TTM value through Dec 2025 reached $58.4 million, up 2.26%, while the annual FY2025 figure was $58.4 million, 2.26% up from the prior year.
  • Shares Outstanding reached $58.4 million in Q4 2025 per AGIO's latest filing, roughly flat from $58.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $74.3 billion in Q2 2025 to a low of $58.3 million in Q3 2025.
  • Average Shares Outstanding over 5 years is $36.3 billion, with a median of $35.6 billion recorded in 2022.
  • Peak YoY movement for Shares Outstanding: surged 100976.86% in 2023, then plummeted 99.92% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $70.6 million in 2021, then increased by 1.0% to $71.3 million in 2022, then increased by 1.27% to $72.2 million in 2023, then decreased by 20.79% to $57.2 million in 2024, then grew by 2.26% to $58.4 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Shares Outstanding are $58.4 million (Q4 2025), $58.3 million (Q3 2025), and $74.3 billion (Q2 2025).